NCT01802320View on ClinicalTrials.gov

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

August 5, 2015

Conditions
Colon Mucinous AdenocarcinomaColon Signet Ring Cell AdenocarcinomaRectal Mucinous AdenocarcinomaRectal Signet Ring Cell AdenocarcinomaRecurrent Colon CarcinomaRecurrent Rectal CarcinomaStage IIIA Colon CancerStage IIIA Rectal CancerStage IIIB Colon CancerStage IIIB Rectal CancerStage IIIC Colon CancerStage IIIC Rectal CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal Cancer
Interventions
DRUG

Akt Inhibitor MK2206

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01802320 - Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter